Ovid Therapeutics Inc. (OVID) — Financial statements
Income statement, balance sheet, and cash flow for Ovid Therapeutics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 7↑1181.3% | 0.57↑44.4% | 0.39↓73.9% | 2↓99.3% | 208 | |
| Cost of Revenue | 0.30 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 7↑1128.3% | 0.57↑44.4% | 0.39↓73.9% | 2↓99.3% | 208 | |
| Operating Expenses | ||||||
| R&D Expenses | 26↓30.4% | 37↑28.6% | 29↑16.1% | 25↓47.6% | 47 | |
| General & Administrative Expenses | 24↓6.1% | 26↓13.2% | 30↓8.8% | 32↓12.9% | 37 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 24↓6.1% | 26↓13.2% | 30↓8.8% | 32↓12.9% | 37 | |
| Other Expenses | -0.30↓30100.0% | 0.00↓99.9% | 2↑294017.6% | 0.00↓53.8% | 0.00 | |
| Operating Expenses | 49↓20.9% | 62↑4.7% | 60↑4.6% | 57↓32.2% | 84 | |
| Total Costs & Expenses | 50↓20.4% | 62↑4.7% | 60↑4.6% | 57↓32.2% | 84 | |
| Operating Results | ||||||
| Operating Income | -42↑31.4% | -62↓4.4% | -59↓6.7% | -56↓144.7% | 124 | |
| Depreciation & Amortization | 0.30↓51.1% | 0.61↑7.9% | 0.57↓58.9% | 1↑482.8% | 0.24 | |
| EBITDA | -42↑27.1% | -58↓1.3% | -57↓5.3% | -54↓143.5% | 124 | |
| EBIT | -42↑27.3% | -58↓1.4% | -58↓3.7% | -56↓144.7% | 124 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓100.0% | 4↓20.4% | 5 | 0.00 | 0.00 | |
| Interest Income | 0.00↓100.0% | 4↓20.4% | 5 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -4↓105.9% | -2↓333233.3% | -0.00↑53.8% | -0.00 | |
| Other Income / Expenses | 25↓29.4% | 35↑410.7% | 7↑403.4% | 1↑3118.5% | -0.05 | |
| Income Before Tax | -17↑34.1% | -26↑49.5% | -52↑3.4% | -54↓143.6% | 124 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 1 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -17↑34.1% | -26↑49.5% | -52↑3.4% | -54↓144.1% | 123 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -17↑34.1% | -26↑49.5% | -52↑3.4% | -54↓144.1% | 123 | |
| Bottom-Line Net Income | -17↑34.1% | -26↑48.6% | -51↑5.1% | -54↓145.2% | 120 | |
| EPS (Basic) | -0.24↑35.1% | -0.37↑50.0% | -0.74↑3.9% | -0.77↓143.3% | 1.78 | |
| EPS (Diluted) | -0.24↑35.1% | -0.37↑50.0% | -0.74↑3.9% | -0.77↓143.8% | 1.76 | |
| Weighted Average Shares | 74↑4.0% | 71↑0.5% | 71↑0.2% | 70↑4.4% | 67 | |
| Weighted Average Diluted Shares | 74↑4.0% | 71↑0.5% | 71↑0.2% | 70↑3.5% | 68 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.